BG-12: New pill shows promise against relapsing multiple sclerosis
The relapse rate was nearly halved after 2 years, researchers find.
(HealthDay)—A new pill can help prevent relapse in some people with multiple sclerosis (MS), new research indicates.
In two studies, the annualized relapse rate was cut nearly in half with twice-daily use of the new drug currently known as BG-12. One study also found that BG-12 could reduce the progression of disability, while the other study found no statistically significant difference between the drug and placebo for rates of disability.
"We found a robust reduction in the annualized relapse rate of 44 percent in the twice-daily group and 51 percent in the thrice-daily group," said Dr. Robert Fox, lead author of one of the studies and medical director at the Mellen Center for MS at the Cleveland Clinic, in Ohio.
Fox added that the drug was well tolerated in the clinical trial, and appears to be quite safe. "It's a pill they take twice a day at home, and there was no increased risk of opportunistic infections or cancer," he noted.
Results of the studies are published in the Sept. 20 issue of the New England Journal of Medicine. Both were funded by the drug's manufacturer, Biogen Idec.
Multiple sclerosis is an autoimmune disease that damages the outside of nerve fibers in the central nervous system, which includes the brain, spine and optic nerves, according to the National Multiple Sclerosis Society (NMSS). Symptoms can include fatigue, numbness in the limbs, balance and coordination problems, bladder or bowel dysfunction, vision problems, pain and even paralysis.
Most people—about 85 percent—have a form of MS that's called relapsing-remitting, according to the NMSS. That means that people have periods where the disease is very active. At other times, the disease remits. During these periods of remission, there may be complete or partial recovery of function, and the disease doesn't progress during remission.
Both of the current studies focused on people with the relapsing-remitting form of MS.
Fox's study included 359 patients taking 240 milligrams (mg) of BG-12 twice a day, 345 taking 240 mg three times a day, 350 taking glatiramer acetate (an injectable MS drug) and 363 taking a placebo. BG-12 was originally developed as a drug to treat the autoimmune skin condition psoriasis.
The annual relapse rate was 0.22 for people taking BG-12 twice a day and 0.20 for those taking it three times a day. The annual relapse rate was 0.29 for glatiramer acetate and 0.40 for those on placebo. There were no statistically significant differences in the rate of disability progression among the groups, according to the study.
The second study included 410 people taking BG-12 twice a day, 416 people taking the drug three times a day and 408 people on placebo.
The annual relapse rate was 0.17 for the twice-daily group, 0.19 in the thrice-daily group and 0.36 in the placebo group. Rates of disability progression were 16 percent in the twice-daily group, 18 percent in the thrice-daily group and 27 percent in the placebo group, according to the study.
"These studies show the potential for another oral treatment for relapsing-remitting MS. They illustrate that trying new strategies and tackling new parts of the immune system can be effective," explained Timothy Coetzee, chief research officer at the National Multiple Sclerosis Society.
"Having a treatment that targets different pathways in the immune system is important. This is an advance in the treatment of MS in my view," Coetzee said.
Fox said that BG-12 appears to modify the immune system response without suppressing the immune system, a common problem with some other medications available for MS. Fox said that the new drug also appears to protect nervous system cells from damage, though how that occurs isn't yet clear.
The U.S. Food and Drug Administration is expected to make a decision on whether or not to approve BG-12 by the end of the year, according to Fox. No information on what the cost of BG-12 will be is currently available.
More information: Learn more about available treatments from the National Multiple Sclerosis Society.
Journal reference: New England Journal of Medicine
Copyright © 2012 HealthDay. All rights reserved.
- Experimental pill may ease multiple sclerosis disability Mar 14, 2012 | not rated yet | 0
- Oral drug for MS significantly reduces disease activity and slows disability Apr 11, 2011 | not rated yet | 0
- New oral drug found to reduce relapses in multiple sclerosis patients Oct 06, 2011 | not rated yet | 0
- Asthma medication may benefit patients with multiple sclerosis Sep 13, 2010 | not rated yet | 0
- New pill to treat multiple sclerosis Apr 30, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
New research presented today shows that formation of new neurons in the hippocampus - a brain region known for its importance in learning and remembering - could cause forgetting of old memories by causing a reorganization ...
Neuroscience 25 minutes ago | not rated yet | 0
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
Neuroscience 45 minutes ago | 3 / 5 (1) | 0
One of the major frontiers of modern science is a comprehensive understanding of the human brain and its functions to guide the development of new technologies in information and communication. In a major announcement for ...
Neuroscience 1 hour ago | not rated yet | 0
(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...
Neuroscience 16 hours ago | 4.8 / 5 (6) | 0 |
(Medical Xpress)—The human brain is able to identify individuals' voices by comparing them against an internal 'average voice' prototype, according to neuroscientists.
Neuroscience 20 hours ago | 1 / 5 (1) | 1 |
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
54 minutes ago | not rated yet | 0 |
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
35 minutes ago | not rated yet | 0
Ernie Pyle – an iconic war correspondent in World War II – reportedly said "There are no atheists in foxholes." A new joint study between two brothers at Cornell and Virginia Wesleyan found that only ...
29 minutes ago | not rated yet | 0
(Medical Xpress)—Research by Stanford scholar Emma Seppala at the Center for Compassion and Altruism Research and Education found that post-traumatic stress disorder decreased in veterans who participated ...
55 minutes ago | not rated yet | 0
The individualisation of drug treatments to support patients to self-manage their conditions is a concept that sits at the heart of policy, but a recent study in BMJ Open shows that there is no concrete defini ...
45 minutes ago | not rated yet | 0
Routinely measuring fractional flow reserve (FFR) using pressure wire assessment during coronary angiography for diagnosis of chest pain leads to significant changes in the management of one in four patients, according to ...
1 hour ago | not rated yet | 0